Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 42-Day Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 And K-833 in Overweight/Obese Patients With Type 2 Diabetes Mellitus

NCT06305351 is registered in ClinicalTrials.gov with Kallyope Inc. as lead sponsor.

NCT NCT06305351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06305351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 42-Day Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 And K-833 in Overweight/Obese Patients With Type 2 Diabetes Mellitus
Lead sponsor
Kallyope Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 7, 2023
Completion date
June 21, 2024
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, type 2 diabetes mellitus (t2dm)